Pharmaceutical intelligence for Shandong New Time Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJune 23, 2026

Phase I Trial of LNF2105 Shows Promise in Advanced Solid Tumors

A Phase I clinical trial is underway to evaluate LNF2105 in patients with advanced solid tumors, focusing on safety and preliminary efficacy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJune 23, 2026

Phase I Trial of LNF2105 Shows Promise in Advanced Solid Tumors

A Phase I clinical trial is underway to evaluate LNF2105 in patients with advanced solid tumors, focusing on safety and preliminary efficacy.

Competitive activity

No signals indexed for this entity yet.

Assets

LNF2105 →

Therapeutic areas

Oncology →

Small Molecule →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.